---
title: "ImmunityBio, Inc. (IBRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IBRX.US.md"
symbol: "IBRX.US"
name: "ImmunityBio, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T16:10:27.840Z"
locales:
  - [en](https://longbridge.com/en/quote/IBRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IBRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IBRX.US.md)
---

# ImmunityBio, Inc. (IBRX.US)

## Company Overview

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [immunitybio.com](https://immunitybio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: C (0.49)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 74 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 351.53% |  |
| Net Profit YoY | -108.88% |  |
| P/B Ratio | -9.63 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8378831816.00 |  |
| Revenue | 140977000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 116.94% | A |
| Profit Margin | -606.15% | E |
| Gross Margin | 99.46% | A |
| Revenue YoY | 351.53% | A |
| Net Profit YoY | -108.88% | E |
| Total Assets YoY | 112.88% | A |
| Net Assets YoY | -47.19% | E |
| Cash Flow Margin | 34.45% | D |
| OCF YoY | 351.53% | A |
| Turnover | 0.30 | D |
| Gearing Ratio | 234.41% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - ImmunityBio, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "351.53%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-108.88%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-9.63",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8378831816.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "140977000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "116.94%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-606.15%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "99.46%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "351.53%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-108.88%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "112.88%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-47.19%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "34.45%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "351.53%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.30",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "234.41%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -9.81 | 451/386 | - | - | - |
| PB | -9.63 | 522/386 | - | - | - |
| PS (TTM) | 59.43 | 238/386 | 77.31 | 63.63 | 37.14 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Overweight | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.46 |
| Highest Target | 23.00 |
| Lowest Target | 12.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IBRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IBRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IBRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IBRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**